Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-06260933 是一种具有高度选择性及口服有活性的MAP4K4小分子抑制剂,在激酶实验中IC50为 3.7 nM,在细胞实验中IC50为 160 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 433 | 现货 | ||
2 mg | ¥ 619 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,580 | 现货 | ||
25 mg | ¥ 3,230 | 现货 | ||
50 mg | ¥ 4,560 | 现货 | ||
100 mg | ¥ 6,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 939 | 现货 |
产品描述 | PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively. |
靶点活性 | MAP4K4:3.7 nM |
体外活性 | PF-06260933 treatment of human aortic endothelial cell (EC) robustly prevents TNF-α-mediated endothelial permeability in vitro. |
体内活性 | PF-06260933 treatment does not alter plasma lipid content in the mice model, although reductions in glucose levels are observed, which is consistent with whole-body-inducible Map4k4 knockout animals. PF-06260933 administration ameliorates further plaque development and/or promotes plaque regression in this animal model (46.0% versus 25.5%), and a reduction in plasma glucose as well as lipid content is also observed. |
别名 | PF-6260933, PF 6260933, PF6260933 |
分子量 | 296.75 |
分子式 | C16H13ClN4 |
CAS No. | 1811510-56-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-06260933 1811510-56-1 MAPK PF-6260933 PF06260933 inhibit MAP4K MAPK Kinase Kinase Kinase PF 6260933 PF 06260933 Inhibitor PF6260933 inhibitor